Additional Relevant Details The FDA has granted Roche's investigational medicine ocrelizumab (OCREVUSTM), for the treatment of people with primary progressive multiple sclerosis (PPMS), breakthrough therapy designation.  "Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible."